During a Case-Based Roundtable® event, Lori J. Wirth, discussed the SELECT trial and the role of multikinase inhibitors in ...

Lenvatinib plus pembrolizumab has improved survival rates for patients with intermediate-stage hepatocellular cancer, ...

Finally, the assay can be used with Merck’s Keytruda (pembrolizumab) and GSK’s Jemperli (dostarlimab) across solid tumors ...

Median overall survival (OS) increased from 19.3 months with upfront immune checkpoint inhibition (ICI) to 41.3 months when a ...

Pharmac has decided to fund lenvatinib from 1 December 2024 for people with some types of thyroid, liver, and kidney cancer. Lenvatinib (branded as Lenvima) stops the number of cancer cells from ...

People with some types of thyroid and liver cancer are getting free access to a targeted treatment for the first time, with ...

According to data from the phase 3 double-blinded, active-controlled, multicenter LEAP-012 trial (NCT04246177), lenvatinib (Lenvima) with pembrolizumab (Keytruda) and transarterial chemoembolization ...

The company’s MI Cancer Seek is approved as a companion diagnostic for multiple cancer therapies, including MSD’s Keytruda, ...

Exelixis Inc (EXEL) reports robust Q3 2024 financials, raises full-year guidance, and strengthens its market position through ...

Results for the lenvatinib-pembrolizumab arm were 32%, 7.2 months, 18.3 months, and 14.4 months, respectively. Of note, the patients in this trial had not received checkpoint inhibitor therapy and ...